Certain NSCLC Subgroups May Not Benefit From Immunotherapy
A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.
United States San Francisco Mark Gramling Society For Immunotherapy Of Cancer Lung Cancer Ung Carcinoma
Source: medscape.com